Irx Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 15-11-2024
- Paid Up Capital ₹ 98.06 K
as on 15-11-2024
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 93.38%
(FY 2023)
- Profit 90.17%
(FY 2023)
- Ebitda 87.45%
(FY 2023)
- Net Worth 195.24%
(FY 2023)
- Total Assets 176.04%
(FY 2023)
About Irx Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 98.06 K , as per Ministry of Corporate Affairs (MCA) records.
Mahipal Sachdev and Ritika Gupta serve as directors at the Company.
- CIN/LLPIN
U24110DL2020PTC371543
- Company No.
371543
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Oct 2020
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Irx Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ritika Gupta  | Director | 14-Oct-2020 | Current |
| Mahipal Sachdev | Director | 14-Oct-2020 | Current |
Financial Performance and Corporate Structure Insights of Irx Pharmaceuticals.
Irx Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 93.38% increase. The company also saw a substantial improvement in profitability, with a 90.17% increase in profit. The company's net worth Soared by an impressive increase of 195.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Irx Pharmaceuticals?
In 2023, Irx Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vishwanethra Health Services Private LimitedActive 15 years 3 monthsMahipal Sachdev and Ritika Gupta are mutual person
Challa Eye Care Private LimitedActive 7 years 6 monthsMahipal Sachdev and Ritika Gupta are mutual person
Dr. Khunger Eye Care And Research Centre Private LimitedActive 14 years 2 monthsMahipal Sachdev and Ritika Gupta are mutual person
- New Delhi Centre For Sight LimitedActive 22 years 6 months
Mahipal Sachdev and Ritika Gupta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Irx Pharmaceuticals?
Irx Pharmaceuticals has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Irx Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Irx Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
